[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported that Board member Craig Eagle resigned from the Board of Directors, effective November 14, 2025. The company states that his resignation was not due to any disagreement with Telomir, its management, or any other Board member. The Board expressed appreciation for his service. A copy of Mr. Eagle’s resignation letter is included as Exhibit 17.1 to this report.

false 0001971532 0001971532 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers.

Director Resignation

On November 14, 2025, Craig Eagle, a member of the Board of Directors (the “Board”) of Telomir Pharmaceuticals Inc. (the “Company”), resigned from the Board, effective immediately. Mr. Eagle’s resignation was not as a result of any disagreement with the Company, the Company’s management, or any other member of the Board. The Board thanks Mr. Eagle for his service to the Company.

A copy of the resignation letter provided by Mr. Eagle to the Registrant is attached as Exhibit 17.1 to this Current Report.

Item 9.01(d) Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
17.1		Resignation Letter from Craig Eagle
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: November 20, 2025	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

FAQ

What did Telomir Pharmaceuticals (TELO) announce in this 8-K?

Telomir Pharmaceuticals, Inc. announced that Board member Craig Eagle resigned from its Board of Directors, effective November 14, 2025, and attached his resignation letter as an exhibit.

Why did Craig Eagle resign from the Telomir Pharmaceuticals (TELO) Board?

The company states that Craig Eagle’s resignation was not the result of any disagreement with Telomir Pharmaceuticals, its management, or any other Board member.

When was the resignation of Craig Eagle from TELO’s Board effective?

Craig Eagle’s resignation from the Telomir Pharmaceuticals Board of Directors was effective November 14, 2025.

Did Telomir Pharmaceuticals (TELO) report any conflicts related to this director resignation?

No conflicts were reported. Telomir Pharmaceuticals states that the resignation was not due to any disagreement with the company, its management, or the Board.

Is the Craig Eagle resignation letter available to investors of TELO?

Yes. The resignation letter from Craig Eagle is filed as Exhibit 17.1, with a cover page interactive data file identified as Exhibit 104.

Does this 8-K disclose any financial results or major transactions for Telomir Pharmaceuticals (TELO)?

No financial results or major transactions are described. The disclosure focuses on the resignation of director Craig Eagle and the related exhibit.